نتایج جستجو برای: i 131
تعداد نتایج: 1050616 فیلتر نتایج به سال:
Retention of iodine in the thyroid gland is the result of renal excretion and transport of iodine to thyroid cells. Both processes are affected by furosemide. The aim of our study was to test whether furosemide influenced radioiodine-131 ((131)I) retention in the thyroid gland of living mice. Our methods were as follows: After 15 days of low-iodine diet, 19 Swiss mice received an intra-peritone...
Objectives: I-131 is a widely used radiopharmaceutical for the management of patients with differentiated thyroid carcinoma (DTC). It is the main agent for the ablation of residual thyroid tissue and the treatment of recurrent or metastatic DTC. However, diagnostic doses of I-131 may cause some form of cell damage “stunning” which reduce subsequent uptake of the therapeutic dose of I-131. In co...
Assessment of myocardial viability is deemed necessary to aid in clinical decision making whether to recommend revascularization therapy for patients with myocardial infarction (MI). Dianthraquinones such as hypericin (Hyp) selectively accumulate in necrotic myocardium, but were unsuitable for early imaging after administration to assess myocardial viability. Since dianthraquinones can be compo...
We demonstrate the use of combination therapy to overcome the limitations of cancer DNA vaccines by adding radioiodine gene therapy in an animal cancer model. We established a stable cell line (CT26/hMUC1-hNIS-Fluc: CMNF) expressing the hMUC1, hNIS and Fluc genes using a retro- and lentivirus system. The survival rates (%) of CMNF cells were determined using clonogenic assays after (131)I treat...
UNLABELLED Radioiodine therapy with (131)I is used for treatment of suspected recurrence of differentiated thyroid carcinoma. Pretherapeutic (124)I PET/CT with a low activity (~1% of (131)I activity) can be performed to determine whether uptake of (131)I, and thereby the desired therapeutic effect, may be expected. However, false-negative (124)I PET/CT results as compared with posttherapeutic (...
UNLABELLED Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I. The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form of cell damage from the diagnostic dosage of the radionuclide. Stunning could pote...
keyword: F-18 FDG PET/CT, resistance to I-131 therapy, cervical lymph node, papillary thyroid cancer Objective: Resistance of metastatic lymph nodes (LNs) to high dose I-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. We evaluated the role of F-18 FDG PET/CT in the prediction of resistance to high dose I-131 therapy in patients with papillary thyroi...
BACKGROUND Little is known about the whole body oxidative stress burden following radioactive iodine ((131)I) therapy of thyroid diseases. METHODS We studied 17 patients with benign nodular goiter treated with (131)I therapy. The targeted thyroid dose was 50 Gy in 11 patients pretreated with 0.1 mg of recombinant human TSH (rhTSH). In 6 patients, the applied thyroid dose was 100 Gy without rh...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید